In a randomized controlled trial in type 2 diabetics, 200 mg of CoQ10 daily for 12 weeks significantly decreased both systolic and diastolic blood pressure, by 6.1 mm Hg and 2.9 mm Hg, respectively
More than 12 well-designed randomized controlled research studies failed to demonstrate any effect of secretin, a gastrointestinal hormone, on ASD symptoms
Resistance Training Protocol: 3-4 sessions per week of strength training stimulates muscle protein synthesis and offsets GLP-1's reduction in protein synthesis rates
Results Differential effects of DHA and DFO on P
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)